Use of molecular markers for predicting therapy response in cancer patients.

Hdl Handle:
http://hdl.handle.net/10147/207579
Title:
Use of molecular markers for predicting therapy response in cancer patients.
Authors:
Duffy, Michael J; O'Donovan, Norma; Crown, John
Affiliation:
Department of Pathology and Laboratory Medicine, St. Vincent's University, Hospital, Dublin, Ireland. Michael.J.Duffy@ucd.ie
Citation:
Cancer Treat Rev. 2011 Apr;37(2):151-9. Epub 2010 Aug 3.
Journal:
Cancer treatment reviews
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207579
DOI:
10.1016/j.ctrv.2010.07.004
PubMed ID:
20685042
Abstract:
Predictive markers are factors that are associated with upfront response or resistance to a particular therapy. Predictive markers are important in oncology as tumors of the same tissue of origin vary widely in their response to most available systemic therapies. Currently recommended oncological predictive markers include both estrogen and progesterone receptors for identifying patients with breast cancers likely to benefit from hormone therapy, HER-2 for the identification of breast cancer patients likely to benefit from trastuzumab, specific K-RAS mutations for the identification of patients with advanced colorectal cancer unlikely to benefit from either cetuximab or panitumumab and specific EGFR mutations for selecting patients with advanced non-small-cell lung cancer for treatment with tyrosine kinase inhibitors such as gefitinib and erlotinib. The availability of predictive markers should increase drug efficacy and decrease toxicity, thus leading to a more personalized approach to cancer treatment.
Language:
eng
MeSH:
Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Biological Markers/analysis; Breast Neoplasms/chemistry/*drug therapy/genetics; Cytochrome P-450 CYP2D6/genetics; Female; Genotype; Humans; Individualized Medicine; Mutation; Proto-Oncogene Proteins/genetics; Quinazolines/therapeutic use; Receptor, Epidermal Growth Factor/analysis/genetics; Receptor, erbB-2/analysis; Receptors, Estrogen/analysis; Receptors, Progesterone/analysis; Tamoxifen/therapeutic use; ras Proteins/genetics
ISSN:
1532-1967 (Electronic); 0305-7372 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorDuffy, Michael Jen_GB
dc.contributor.authorO'Donovan, Normaen_GB
dc.contributor.authorCrown, Johnen_GB
dc.date.accessioned2012-02-01T10:31:55Z-
dc.date.available2012-02-01T10:31:55Z-
dc.date.issued2012-02-01T10:31:55Z-
dc.identifier.citationCancer Treat Rev. 2011 Apr;37(2):151-9. Epub 2010 Aug 3.en_GB
dc.identifier.issn1532-1967 (Electronic)en_GB
dc.identifier.issn0305-7372 (Linking)en_GB
dc.identifier.pmid20685042en_GB
dc.identifier.doi10.1016/j.ctrv.2010.07.004en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207579-
dc.description.abstractPredictive markers are factors that are associated with upfront response or resistance to a particular therapy. Predictive markers are important in oncology as tumors of the same tissue of origin vary widely in their response to most available systemic therapies. Currently recommended oncological predictive markers include both estrogen and progesterone receptors for identifying patients with breast cancers likely to benefit from hormone therapy, HER-2 for the identification of breast cancer patients likely to benefit from trastuzumab, specific K-RAS mutations for the identification of patients with advanced colorectal cancer unlikely to benefit from either cetuximab or panitumumab and specific EGFR mutations for selecting patients with advanced non-small-cell lung cancer for treatment with tyrosine kinase inhibitors such as gefitinib and erlotinib. The availability of predictive markers should increase drug efficacy and decrease toxicity, thus leading to a more personalized approach to cancer treatment.en_GB
dc.language.isoengen_GB
dc.subject.meshAntibodies, Monoclonal/therapeutic useen_GB
dc.subject.meshAntibodies, Monoclonal, Humanizeden_GB
dc.subject.meshBiological Markers/analysisen_GB
dc.subject.meshBreast Neoplasms/chemistry/*drug therapy/geneticsen_GB
dc.subject.meshCytochrome P-450 CYP2D6/geneticsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshGenotypeen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIndividualized Medicineen_GB
dc.subject.meshMutationen_GB
dc.subject.meshProto-Oncogene Proteins/geneticsen_GB
dc.subject.meshQuinazolines/therapeutic useen_GB
dc.subject.meshReceptor, Epidermal Growth Factor/analysis/geneticsen_GB
dc.subject.meshReceptor, erbB-2/analysisen_GB
dc.subject.meshReceptors, Estrogen/analysisen_GB
dc.subject.meshReceptors, Progesterone/analysisen_GB
dc.subject.meshTamoxifen/therapeutic useen_GB
dc.subject.meshras Proteins/geneticsen_GB
dc.titleUse of molecular markers for predicting therapy response in cancer patients.en_GB
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St. Vincent's University, Hospital, Dublin, Ireland. Michael.J.Duffy@ucd.ieen_GB
dc.identifier.journalCancer treatment reviewsen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.